BTIG Reiterates Buy Rating on ORIC Pharmaceuticals, Inc. (ORIC)

Market Context

ORIC Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $9.30 with a market capitalization of $944.7M. The stock has declined 28.1% over the past 52 weeks.

Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ORIC Pharmaceuticals, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ORIC Pharmaceuticals, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 28, 2026	BTIG	Buy	N/A
Oct 27, 2026	Wedbush	Outperform	N/A
Oct 26, 2026	Stifel	Buy	N/A
Oct 14, 2026	JP Morgan	Overweight	N/A
Oct 05, 2026	Leerink Partners	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View ORIC Stock Page